drugset / Trial / NCT02127034

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

NCT02127034

Phase 1 Completed 26 enrolled Astellas Pharma Europe B.V.
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate the effect of steady state solifenacin and mirabegron on the pharmacokinetics of co-administered steady state digoxin. This study will also evaluate the safety and tolerability of the combined steady state administration of solifenacin, mirabegron and digoxin.

Timeline

Start
2014-03
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified Oral
Subject Mirabegron Other / unclassified Oral
Subject Solifenacin Small molecule Oral

Indications

No indication recorded.